The Second David Sackett Symposium THE RANDOMIZED TRIAL AS ROYALTY
|
|
- Cori Poole
- 5 years ago
- Views:
Transcription
1 The Second David Sackett Symposium THE RANDOMIZED TRIAL AS ROYALTY John Concato, MD, MS, MPH Yale University School of Medicine VA Clinical Epidemiology Research Center 27 September 2013
2 DISCLOSURE John Concato has no potential for conflict of interest with this presentation
3 OBJECTIVES Understand specific strengths and limitations of observational studies and randomized trials Appreciate need for methodological and clinical judgment when evaluating patient-oriented research
4 Oxford Dictionary: DEFINITIONS OF ROYAL people of royal blood or status; member of a royal family the status or power of a king or queen the most successful, famous, or highly regarded members of a particular group
5 RCT AS KING OF STUDY DESIGN Grades of evidence for study design: I: At least one properly randomized, controlled trial (RCT) II-1: Well-designed trials without randomization II-2: Well-designed cohort or case-control analytic studies, preferably multi-site II-3: Multiple time series with or without the intervention, or dramatic results in uncontrolled experiments (e.g., penicillin or insulin) III: Opinions of respected authorities, based on clinical experience; descriptive studies, case reports, expert committee reports (US Preventive Services Task Force 1996)
6 STUDY DESIGN IN BROADER CONTEXT Validity study architecture: randomize, adjust for confounding, etc. source of data: primary, secondary, pooled, etc. Note: observational studies don t always use 2 o data Generalizability intended spectrum based on inclusion/exclusion criteria potential impact of participation itself (e.g., Hawthorne effect) Note: observational studies have inherent advantage
7 EMPHASIS RE: STUDY DESIGN Architecture Strengths Limitations Randomized trials a a Observational studies a a
8 LIMITATIONS OF RCTs Randomized trials on same topic often contradictory e.g., Horwitz Am J Med 1987;82:498 to be expected, but discordance is often overlooked Meta-analyses and large/simple RCTs often don t agree e.g., LeLorier New Engl J Med 1997;337:536 under-appreciated; attributed partly to heterogeneity RCTs can have restricted generalizability e.g., Coca JAMA 2006;296:1377 acknowledged, but implications are often minimized
9 RCT GENERALIZABILITY (cont d) Coca, et al., JAMA 2006;296:1377 (cont d) [Cardiovascular RCTs] do not provide adequate information on the effect of interventions on patients with renal disease Juurlink, et al., New Engl J Med 2004;351:543 Publication of [spironolactone RCT] was associated with abrupt increases in hyperkalemia-associated morbidity and mortality. Luce, et al., Ann Intern Med 2009;151:206 many RCTs are ill suited to meet the evidentiary needs implicit in the [Inst of Med] definition of [comp effectiveness research]
10 SPECTRUM OF OBSERVATIONAL STUDIES Indirect cause-and-effect evidence: ecological study (unit of observation is >1 patient/person) case series (no comparison group) historical control trial (non-concurrent comparison group) Direct cause-and-effect evidence: observational cohort study (with concurrent comparison) case-control study (including nested within cohort)
11 STRENGTHS OF OBSERVATIONAL STUDIES Strategies can promote validity of observational methods e.g., Horwitz Am J Med 1990;89:630 (including RCT-like restricted cohort, specific zero-time for intervention) Non-randomized treatments are effective/safe e.g., Tsimberidou J Clin Oncol 2009;27:6243 (including bleomycin, cisplatin, etoposide for testicular cancer) Observational studies and RCTs often agree head-to-head e.g., Concato New Engl J Med 2000;342:1887 ( welldesigned observational studies do not systematically overestimate [results when compared with RCTs] )
12 OBSERV STUDIES & RCTs AGREE (cont d) McKee, et al., BMJ 1999;319:312 one method does not give a consistently greater effect Benson and Hartz, New Engl J Med 2000;342:1887 [Observational results are] neither consistently larger than nor qualitatively different from those obtained in RCTs Ligthelm, et al., Clin Ther 2007;29:1284 observational studies can be conducted using the same exacting and rigorous standards as are used for RCTs
13 PREDICTION RE: RANDOMIZED TRIALS Alvan R. Feinstein
14 PROBLEM OF CONFOUNDING Confounding factors threaten validity of observ. study, whereas randomization tends to balance such factors
15 HOW TO DEAL WITH CONFOUNDING Several available options: conduct only randomized, controlled trials (per EBM) use methods that substitute for randomization (e.g., propensity scores, instrumental variables) use traditional observational methods rigorously Current emphasis is problematic: expectation of requiring RCT or complex model observational studies held in low regard
16 VARIABLE IMPACT OF CONFOUNDING Status of confounding factors implications for study: known, not accounted for major methodological weakness known & accounted for sound research practice unknown clinicians would not treat preferentially, reducing potential for bias Note: extent of problem varies (as with limitations of RCTs)
17 EVIDENCE-BASED MEDICINE (EBM) APPROACH Validity: whether results are true for patients enrolled in the trial or observational study Generalizability: whether the results generalize to a broader population of patients with condition Validity is considered to be of primary importance; generalizability is considered subsequently
18 BEYOND RANDOMISED VS. OBSERVATIONAL STUDIES Accuracy: whether results are true for patients who would receive exposure, intervention, etc.; Consider validity and generalizability together (Concato & Horwitz, Lancet 2004;363:1660)
19 MEDICINE-BASED EVIDENCE (MBE) In a medicine-based evidence approach, the primary emphasis is on clinically relevant issues of who and where were the patients, what and why were the treatments, & when and how were the outcomes measured as well as an assessment of validity and generalizability considered together and denoted as accuracy. (Concato JAMA 2012; 307:1641)
20 EXAMPLE #1: HORMONE REPLACEMENT THERAPY Research question: Does hormone replacement therapy (HRT) for post-menopausal women improve health outcomes? Observational studies: showed benefit of HRT regarding cardiovascular outcomes RCTs: showed early cardiovascular harm from HRT Conventional wisdom: RCTs are correct, observational studies are flawed; problem is inherent to type of research design
21 EXAMPLE #1: RCT/OBS STUDIES FOR HRT Relative risks or odds ratios from: Outcome RCTs Observational Colorectal ca 0.63 ( ) 0.66 ( ) Hip fracture 0.66 ( ) 0.75 ( ) Stroke 1.41 ( ) 1.45 ( ) Pulm emb 2.13 ( ) 2.1 ( ) (Grodstein New Engl J Med 2003;348:645)
22 EXAMPLE #1: RCT/OBS STUDIES FOR HRT Relative risks or odds ratios from: Outcome RCTs Observational Colorectal ca 0.63 ( ) 0.66 ( ) Hip fracture 0.66 ( ) 0.75 ( ) Stroke 1.41 ( ) 1.45 ( ) Pulm emb 2.13 ( ) 2.1 ( ) Coronary dz 1.29 ( ) 0.61 ( ) (Grodstein New Engl J Med 2003;348:645)
23 EXAMPLE #1: MEDICINE-BASED EVIDENCE Hormone replacement & coronary disease: Patients: Exposure: Outcome: time since menopause socioeconomic status dose of drug(s) duration of treatment timing of treatment duration of follow-up capture of early events? equal detection of MIs?
24 HRT & CV OUTCOMES: OBSERVATIONAL STUDIES Not adjusted for socioeconomic status: Adjusted for socioeconomic status: (Von Elm BMJ 2004;329:869)
25 TIMING OF HRT VS. ONSET OF MENOPAUSE For randomised trials, [the start of HRT] is the natural analysis because therapy starts at randomisation the first years of hormone replacement by combined oestrogen-progestin did increase coronary heart disease, which then waned. Most current users [in observational studies] were past the window wherein coronary heart disease risk was increased when data from the observational part of the [WHI trial] were reanalysed according to time since start of therapy, the same pattern emerged of an initial increase in risk, followed by a decrease. (Vandenbroucke Lancet 2009;373:1233)
26 EXAMPLE #1: IMPLICATIONS Laine Ann Intern Med 2002;137:290 Thus, rather than HRT keeping women healthy, healthy women were taking HRT. Vandenbroucke Lancet 2009;373:1233 Thus nothing was intrinsically wrong with the observational data; what went wrong was an analysis that had not taken into account that the effect of HRT might be different over time Neither design [RCT nor observational] help superior truth.
27 EXAMPLE #2: SCREENING FOR PROSTATE CANCER Observational studies: did not confirm benefit of screening with prostate-specific antigen (PSA), but were dismissed as inferior evidence RCTs: Two major RCTs were launched 20 years ago Superficial assessment: await pronouncement from RCTs, because observational studies are flawed Recent history: results from the trials eagerly anticipated as of 2009, yet RCTs on same topic often don t agree
28 EXAMPLE #2: RCT EXCLUSIVITY United States Preventive Services Task Force (USPSTF) 2008 recommendations on screening with PSA: Although the 2002 USPSTF review considered case-control studies and ecological data related to this key question, we excluded these study types from this part of the evidence update to avoid potential sources of confounding that are inherent in nonrandomized studies. (USPSTF Ann Intern Med 2008;149:192)
29 [King] Perspective when writing: ongoing RCTs may not be definitive. Statement (in Discussion): we should recognize that the [King s pronouncement] (i.e., results of the RCTs) may not provide a definite answer to the question of whether screening with PSA decreases mortality. (Cancer J 2009;15:7-12)
30 EXAMPLE #2: RCTs & OBSERVATIONAL STUDIES PSA screening and prostate-cancer mortality: RCT (Schroder 2009); HR = 0.80 ( ) RCT (Andriole 2009); HR = 1.13 ( ) Case-control (Weinmann 2004); OR = 0.70 ( ) Case-control (Concato 2006); OR = 1.13 ( ) Note: results of the two RCTs are contradictory ; RCT & observational study results overlap
31 EXAMPLE #2: ROYAL DECREE Amer Urol Assoc (AUA) 2009 Best-Practice update: Because there is now evidence from a RCT regarding a mortality decrease associated with PSA screening, the AUA is recommending PSA screening, as proposed in this document, for well-informed men who wish to pursue early diagnosis.
32 EXAMPLE #2: MEDICINE-BASED EVIDENCE Issues re: screening for prostate cancer & mortality: Patients: Exposure: Outcome: age; comorbidity indolent vs. aggressive cancer PSA alone (vs. velocity, density, etc.) with or without digital rectal exam? compared to usual care? overall vs. cause-specific mortality consider morbidity? duration of follow-up
33 SPECTRUM OF VIEWS ON RESEARCH DESIGN Randomized trials or observational tribulations? Only randomized treatment assignment can provide a reliably unbiased estimate of treatment effects perhaps we have not tried hard enough to convert the skeptics. (Pocock, New Engl J Med 2000;342:1907) Why there s no cause to randomize None of [the arguments in favor of randomization] supplies any practical reason for thinking of randomization as having unique epistemic power It is in fact very difficult to see any cogent reason for thinking as highly of RCTs as the medical community does (Worrall, Brit J Phil Sci 2007;58:451)
34 CRITICISM OF ROYAL STATUS GIVEN TO RCTs Decisions should be based on best available evidence, to avoid: RCT-myopia action only justified by RCTs Evidence-based paralysis no action without RCTs (Ziemer Arch Intern Med 2006;166:1672)
35 DISCUSSION IN LAY PRESS Sep 16, 2007 Do We Really Know What Makes Us Healthy? remain skeptical until a randomized trial is done.
36 RESPONSE AS LETTER-TO-EDITOR The take-home message for readers should be not to expect certainty from any individual study, observational or randomized. Progress in science is iterative and incremental in the long run, we get closer to truth as overall evidence accumulates on a given topic. Putting what we know into practice would prevent more disease than [bowing before the throne] of randomized trials. John Concato, M.D., The New York Times, Sep. 30, 2007
37 SUMMARY Science as experiment; science as observation The importance lies not in arguing about which methodology is better than the other, but what can be learned about disease activity and therapy from each type of study. (Chakravarty, Nat Clin Pract Rheumatol 2006;6:286) On the evidence for decisions [re:] therapeutic interventions Decision makers need to assess and appraise all the available evidence irrespective of whether it has been derived from randomised controlled trials or observational studies, and the strengths and weaknesses of each need to be understood. [There is] no shame in accepting that judgments are required. (Rawlins, Lancet 2008;372:2152)
38 TAKE-HOME MESSAGES Carefully-designed observational studies can address confounding adequately; limitations of RCTs are often overlooked; results from both designs are informative Patient-oriented research needs more Medicine-Based Evidence, i.e., more methodological and clinical judgment
EVIDENCE AND RECOMMENDATION GRADING IN GUIDELINES. A short history. Cluzeau Senior Advisor NICE International. G-I-N, Lisbon 2 November 2009
EVIDENCE AND RECOMMENDATION GRADING IN GUIDELINES A short history Françoise Cluzeau Senior Advisor NICE International G-I-N, Lisbon 2 November 2009 Long ago.. Before grading Evidence? Plato (3 rd Century
More informationPros and cons with registry-based research
Pros and cons with registry-based research Måns Rosén SBU My focus this time is on clinical studies more than on etiologic research Health data registers Cancer Register Medical Birth Register including
More informationObjectives. Information proliferation. Guidelines: Evidence or Expert opinion or???? 21/01/2017. Evidence-based clinical decisions
Guidelines: Evidence or Expert opinion or???? Objectives Need for guidelines? Prakesh Shah Professor, Department of Pediatrics, Mount Sinai Hospital Institute of Health Policy Management and Evaluation
More informationOutcomes With "Watchful Waiting" in Prostate Cancer in US Now So Good, Active Treatment May Not Be Better
1 sur 5 19/09/2009 07:02 www.medscape.com From Medscape Medical News Outcomes With "Watchful Waiting" in Prostate Cancer in US Now So Good, Active Treatment May Not Be Better Zosia Chustecka September
More informationPSA Screening and Prostate Cancer. Rishi Modh, MD
PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University
More informationObservational Methods in Comparative Effectiveness Research
Clinical Research Study Observational Methods in Comparative Effectiveness Research John Concato, MD, MS, MPH, a,b Elizabeth V. Lawler, DSc, c,e Robert A. Lew, PhD, c,d J. Michael Gaziano, MD, MPH, c,e
More informationThe Healthy User Effect: Ubiquitous and Uncontrollable S. R. Majumdar, MD MPH FRCPC FACP
The Healthy User Effect: Ubiquitous and Uncontrollable S. R. Majumdar, MD MPH FRCPC FACP Professor of Medicine, Endowed Chair in Patient Health Management, Health Scholar of the Alberta Heritage Foundation,
More informationImproving reporting for observational studies: STROBE statement
Improving reporting for observational studies: STROBE statement Technical meeting on the reporting of human studies submitted for the scientific substantiation of health claims EFSA Parma 20 November 2013
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Understand goal of measurement and definition of accuracy Describe the threats to causal
More informationWashington, DC, November 9, 2009 Institute of Medicine
Holger Schünemann, MD, PhD Chair, Department of Clinical Epidemiology & Biostatistics Michael Gent Chair in Healthcare Research McMaster University, Hamilton, Canada Washington, DC, November 9, 2009 Institute
More informationCRITICAL APPRAISAL OF CLINICAL PRACTICE GUIDELINE (CPG)
CRITICAL APPRAISAL OF CLINICAL PRACTICE GUIDELINE (CPG) Atiporn Ingsathit MD, PhD. 1 Rationale for Clinical Practice Guidelines Worldwide concerns about: Unexplained variations in clinical practice Rising
More informationCancer Screening: Evidence, Opinion and Fact Dialogue on Cancer April Ruth Etzioni Fred Hutchinson Cancer Research Center
Cancer Screening: Evidence, Opinion and Fact Dialogue on Cancer April 2018? Ruth Etzioni Fred Hutchinson Cancer Research Center Three thoughts to begin 1. Cancer screening is a good idea in principle Detect
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
More informationPSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC
PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC Disclosures Faculty / Speaker s name: Darrel Drachenberg Relationships with commercial interests: Grants/Research Support: None Speakers Bureau/Honoraria:
More informationProstate Cancer Screening: Con. Laurence Klotz Professor of Surgery, Sunnybrook HSC University of Toronto
Prostate Cancer Screening: Con Laurence Klotz Professor of Surgery, Sunnybrook HSC University of Toronto / Why not PSA screening? Overdiagnosis Overtreatment Risk benefit ratio unfavorable Flaws of PSA
More informationResponse to United States Preventative Services Task Force draft PSA Screening recommendation: Donald B. Fuller, M.D. Genesis Healthcare Partners
Response to United States Preventative Services Task Force draft PSA Screening recommendation: Donald B. Fuller, M.D. Genesis Healthcare Partners October 2011 Cancer Incidence Statistics, 2011 CA: A Cancer
More informationRole of evidence from observational studies in the process of health care decision making
Role of evidence from observational studies in the process of health care decision making Jan van der Meulen Health Services Research Unit London School of Hygiene and Tropical Medicine Clinical Effectiveness
More informationWHI, HERS y otros estudios: Su significado en la clinica diária. Manuel Neves-e-Castro
WHI, HERS y otros estudios: Su significado en la clinica diária III Congreso Ecuatoriano de Climaterio Menopausia y Osteoporosis por Manuel Neves-e-Castro (Lisboa-Portugal) Julho, 2003 Machala The published
More informationThe who, what, why, where, and when of Clinical Practice Guidelines (CPGs)
The who, what, why, where, and when of Clinical Practice Guidelines (CPGs) Appraisal of Guidelines for Research and Evaluation (AGREE) II DOMAIN 1. SCOPE AND PURPOSE DOMAIN 2. STAKEHOLDER INVOLVEMENT DOMAIN
More informationAssurance Engagements Other than Audits or Review of Historical Financial Statements
Issued December 2007 International Standard on Assurance Engagements Assurance Engagements Other than Audits or Review of Historical Financial Statements The Malaysian Institute Of Certified Public Accountants
More informationExamining the Efficacy of Screening with Prostate- Specific Antigen Testing in Reducing Prostate Cancer Mortality
St. Catherine University SOPHIA Master of Arts/Science in Nursing Scholarly Projects Nursing 5-2012 Examining the Efficacy of Screening with Prostate- Specific Antigen Testing in Reducing Prostate Cancer
More informationOtis W. Brawley, MD, MACP, FASCO, FACE
Otis W. Brawley, MD, MACP, FASCO, FACE Chief Medical and Scientific Officer American Cancer Society Professor of Hematology, Medical Oncology, Medicine and Epidemiology Emory University Atlanta, Georgia
More informationRobert Temple, MD Deputy Center Director for Clinical Science Center for Drug Evaluation and Research Food and Drug Administration
Robert Temple, MD Deputy Center Director for Clinical Science Center for Drug Evaluation and Research Food and Drug Administration USE OF REAL WORLD DATA ( BIG DATA ) FOR REGULATORY PURPOSES ISCTM Meeting
More informationCausation Assessment and Methodology
Causation Assessment and Methodology Kurt T. Hegmann, MD, MPH University of Utah Content Attestation I, Kurt Hegmann, MD hereby declare that the content for this activity, including any presentation of
More informationInterpreting Evidence Based Research: Carpe Diem or Caveat Lector? Jonathan C. Routh, MD, MPH March 10, 2017
Interpreting Evidence Based Research: Carpe Diem or Caveat Lector? Jonathan C. Routh, MD, MPH March 10, 2017 Disclosures I have no relevant financial relationships with the manufacturer(s) of any commercial
More informationEvidence-based medicine and guidelines: development and implementation into practice
Evidence-based medicine and guidelines: development and implementation into practice PD Dr D. Aujesky, MSc MER Médecin-adjoint Service de Médecine Interne CHUV 1 Goals To discuss the basics of evidence-based
More informationRANDOMIZED, CONTROLLED TRIALS, OBSERVATIONAL STUDIES, AND THE HIERARCHY OF RESEARCH DESIGNS
RANDOMIZED, CONTROLLED TRIALS, OBSERVATIONAL STUDIES, AND THE HIERARCHY OF RESEARCH DESIGNS RANDOMIZED, CONTROLLED TRIALS, OBSERVATIONAL STUDIES, AND THE HIERARCHY OF RESEARCH DESIGNS JOHN CONCATO, M.D.,
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
More informationPROSTATE CANCER SCREENING: AN UPDATE
PROSTATE CANCER SCREENING: AN UPDATE William G. Nelson, M.D., Ph.D. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins American Association for Cancer Research William G. Nelson, M.D., Ph.D. Disclosures
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationSystematic reviews: From evidence to recommendation. Marcel Dijkers, PhD, FACRM Icahn School of Medicine at Mount Sinai
Systematic reviews: From evidence to recommendation Session 2 - June 18, 2014 Going beyond design, going beyond intervention: The American Academy of Neurology (AAN) Clinical Practice Guideline process
More informationRethinking Breast Cancer Screening
Rethinking Breast Cancer Screening NAMS Meeting, October, 2014 Russell Harris, MD, MPH University of North Carolina, Chapel Hill Conflicts of Interest Financial: none Intellectual: I have been researching
More informationLarge trials vs observational studies in assessing benefit and harm: the example of aprotinin
Large trials vs observational studies in assessing benefit and harm: the example of aprotinin Dean A. Fergusson, MHA, PhD Senior Scientist and Associate Director, Clinical Epidemiology Program, Ottawa
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationLearning objectives. Examining the reliability of published research findings
Examining the reliability of published research findings Roger Chou, MD Associate Professor of Medicine Department of Medicine and Department of Medical Informatics and Clinical Epidemiology Scientific
More informationMeta-Analysis. Zifei Liu. Biological and Agricultural Engineering
Meta-Analysis Zifei Liu What is a meta-analysis; why perform a metaanalysis? How a meta-analysis work some basic concepts and principles Steps of Meta-analysis Cautions on meta-analysis 2 What is Meta-analysis
More informationSystematic Reviews and Meta- Analysis in Kidney Transplantation
Systematic Reviews and Meta- Analysis in Kidney Transplantation Greg Knoll MD MSc Associate Professor of Medicine Medical Director, Kidney Transplantation University of Ottawa and The Ottawa Hospital KRESCENT
More informationPre-test. Prostate Cancer The Good News: Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest
Pre-test Matthew R. Cooperberg, MD, MPH UCSF 40 th Annual Advances in Internal Medicine Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest 1. I do not offer routine PSA screening, and
More informationThe Evolving Role of PSA for Prostate Cancer. The Evolving Role of PSA for Prostate Cancer: 10/30/2017
The Evolving Role of PSA for Prostate Cancer Adele Marie Caruso, DNP, CRNP Adult Nurse Practitioner Perelman School of Medicine at the University of Pennsylvania November 4, 2017 The Evolving Role of PSA
More informationRecent developments for combining evidence within evidence streams: bias-adjusted meta-analysis
EFSA/EBTC Colloquium, 25 October 2017 Recent developments for combining evidence within evidence streams: bias-adjusted meta-analysis Julian Higgins University of Bristol 1 Introduction to concepts Standard
More informationResearch in Real-World Settings: PCORI s Model for Comparative Clinical Effectiveness Research
Research in Real-World Settings: PCORI s Model for Comparative Clinical Effectiveness Research David Hickam, MD, MPH Director, Clinical Effectiveness & Decision Science Program April 10, 2017 Welcome!
More informationUpdates In Cancer Screening: Navigating a Changing Landscape
Updates In Cancer Screening: Navigating a Changing Landscape Niharika Dixit, MD I have no conflict of interest. 1 Why Should You Care Trends in Cancer Incidence by Site United States. Siegal Et al: CA
More informationObjectives. Prostate Cancer Screening and Surgical Management
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Objectives Update
More informationVirtual Mentor American Medical Association Journal of Ethics January 2013, Volume 15, Number 1:
Virtual Mentor American Medical Association Journal of Ethics January 2013, Volume 15, Number 1: 51-55. POLICY FORUM Evidence-Based Guidelines and Quality Measures in the Care of Older Adults Erika Ramsdale,
More informationLess is more: Guidelines
ESIM Summer School June 20 Friday, 2014 Less is more: Guidelines Primiano Iannone, MD Head of Emergency Department Ospedali del Tigullio, Lavagna (GE) Italy layout What is a clinical guideline Why do we
More informationINTERNATIONAL STANDARD ON ASSURANCE ENGAGEMENTS 3000 ASSURANCE ENGAGEMENTS OTHER THAN AUDITS OR REVIEWS OF HISTORICAL FINANCIAL INFORMATION CONTENTS
INTERNATIONAL STANDARD ON ASSURANCE ENGAGEMENTS 3000 ASSURANCE ENGAGEMENTS OTHER THAN AUDITS OR REVIEWS OF HISTORICAL FINANCIAL INFORMATION (Effective for assurance reports dated on or after January 1,
More informationSystematic Reviews. Simon Gates 8 March 2007
Systematic Reviews Simon Gates 8 March 2007 Contents Reviewing of research Why we need reviews Traditional narrative reviews Systematic reviews Components of systematic reviews Conclusions Key reference
More informationBlood Pressure and Complications in Individuals with Type 2 Diabetes and No Previous Cardiovascular Disease. ID BMJ
1 Blood Pressure and Complications in Individuals with Type 2 Diabetes and No Previous Cardiovascular Disease. ID BMJ 2016.033440 Dear Editor, Editorial Committee and Reviewers Thank you for your appreciation
More informationFIRST DO NO HARM: AN EBM ODYSSEY. Cathleen Colón-Emeric, MD, MHS Geriatrics, Department of Medicine Durham VA GRECC
FIRST DO NO HARM: AN EBM ODYSSEY Cathleen Colón-Emeric, MD, MHS Geriatrics, Department of Medicine Durham VA GRECC colon001@mc.duke.edu 919 660-7517 Learning Objectives 1. Describe the types of studies
More informationDisclosures. Introduction The Bone Crisis. Presentation Outline 12/1/17
Disclosures Building and Translating Evidence-Based Nutrition and Bone Research into Policy and Public Health Messaging Taylor C. Wallace, PhD, CFS, FACN Think Healthy Group & George Mason University George
More informationBSO, HRT, and ERT. No relevant financial disclosures
BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures
More informationOBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP
OBSERVATIONAL Patient-centered observational analytics: New directions toward studying the effects of medical products Patrick Ryan on behalf of OMOP Research Team May 22, 2012 Observational Medical Outcomes
More informationFinancial Disclosures. Prostate Cancer Screening and Surgical Management
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Financial Disclosures
More informationMINI SYMPOSIUM - EUMASS - UEMASS European Union of Medicine in Assurance and Social Security
MINI SYMPOSIUM - EUMASS - UEMASS European Union of Medicine in Assurance and Social Security Quality of Evidence and Grades of Recommendations in guidelines A role for insurance medicine? Prof. Regina
More informationCRITICAL APPRAISAL AP DR JEMAIMA CHE HAMZAH MD (UKM) MS (OFTAL) UKM PHD (UK) DEPARTMENT OF OPHTHALMOLOGY UKM MEDICAL CENTRE
CRITICAL APPRAISAL AP DR JEMAIMA CHE HAMZAH MD (UKM) MS (OFTAL) UKM PHD (UK) DEPARTMENT OF OPHTHALMOLOGY UKM MEDICAL CENTRE MINGGU PENYELIDIKAN PERUBATAN & KESIHATAN PPUKM Lecture content Introduction
More informationComplications of Proton Pump Inhibitor Therapy. Gastroenterology 2017; 153:35-48 발표자 ; F1 김선화
Complications of Proton Pump Inhibitor Therapy Gastroenterology 2017; 153:35-48 발표자 ; F1 김선화 Background Proton pump inhibitors (PPIs) are among the most commonly prescribed medicines for gastroesophageal
More informationKey outcomes for studies on breast cancer screening
Key outcomes for studies on breast cancer screening Mireille Broeders, PhD 10 December 2015, Plenary ECIBC, Baveno Dept for Health Evidence, Radboudumc & Dutch Reference Centre for Screening, Nijmegen,
More informationPubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH
PubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH Instructor: Chap T. Le, Ph.D. Distinguished Professor of Biostatistics Basic Issues: COURSE INTRODUCTION BIOSTATISTICS BIOSTATISTICS is the Biomedical
More informationPurpose. Study Designs. Objectives. Observational Studies. Analytic Studies
Purpose Study Designs H.S. Teitelbaum, DO, PhD, MPH, FAOCOPM AOCOPM Annual Meeting Introduce notions of study design Clarify common terminology used with description and interpretation of information collected
More informationAcknowledgments: Maureen Rice, Rachel Warren, Judy Brown, Meghan Kenny, Sharon Peck-Reid, Sarah Connor Gorber
Screening for prostate cancer with prostate specific antigen and treatment of early-stage or screen-detected prostate cancer: a systematic review of the clinical benefits and harms May 2014 Lesley Dunfield
More informationSelecting a research method
Selecting a research method Tomi Männistö 13.10.2005 Overview Theme Maturity of research (on a particular topic) and its reflection on appropriate method Validity level of research evidence Part I Story
More informationCAN EFFECTIVENESS BE MEASURED OUTSIDE A CLINICAL TRIAL?
CAN EFFECTIVENESS BE MEASURED OUTSIDE A CLINICAL TRIAL? Mette Nørgaard, Professor, MD, PhD Department of Clinical Epidemiology Aarhus Universitety Hospital Aarhus, Denmark Danish Medical Birth Registry
More informationCritical Appraisal Series
Definition for therapeutic study Terms Definitions Study design section Observational descriptive studies Observational analytical studies Experimental studies Pragmatic trial Cluster trial Researcher
More informationAuditing Standards and Practices Council
Auditing Standards and Practices Council Philippine Standard on Assurance Engagements 3000 (Revised) ASSURANCE ENGAGEMENTS OTHER THAN AUDITS OR REVIEWS OF HISTORICAL FINANCIAL INFORMATION PHILIPPINE STANDARD
More informationCritical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death. Debra Moy Faculty of Pharmacy University of Toronto
Critical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death Debra Moy Faculty of Pharmacy University of Toronto Goal To provide practitioners with a systematic approach to evaluating a meta analysis
More informationNICE Guidelines for HTA Issues of Controversy
NICE Guidelines for HTA Issues of Controversy Mark Sculpher, PhD Professor of Health Economics University of York, UK LMI, Medicines Agency in Norway and the Norwegian Knowledge Centre for the Health Services:
More informationCRITICAL APPRAISAL OF MEDICAL LITERATURE. Samuel Iff ISPM Bern
CRITICAL APPRAISAL OF MEDICAL LITERATURE Samuel Iff ISPM Bern siff@ispm.unibe.ch Contents Study designs Asking good questions Pitfalls in clinical studies How to assess validity (RCT) Conclusion Step-by-step
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationOverview of Research Design in Epidemiology
Journal of Law and Policy Volume 12 Issue 2 Article 2 2004 Overview of Research Design in Epidemiology John Concato Follow this and additional works at: http://brooklynworks.brooklaw.edu/jlp Recommended
More informationU.S. Preventive Services Task Force: Draft Prostate Cancer Screening Recommendation (April 2017)
1 U.S. Preventive Services Task Force: Draft Prostate Cancer Screening Recommendation (April 2017) Alex Krist MD MPH Professor and Director of Research Department of Family Medicine and Population Health
More informationRight Answers, Wrong Ques2ons. Ralph I Horwitz
Right Answers, Wrong Ques2ons Ralph I Horwitz Disclosures Employed by GlaxoSmithKline Views expressed reflect mine alone and not those of GSK Right Answer, Wrong Ques2on A young couple moves into an apartment
More informationScreening for Prostate Cancer US Preventive Services Task Force Recommendation Statement
Clinical Review & Education JAMA US Preventive Services Task Force RECOMMENDATION STATEMENT Screening for Prostate Cancer US Preventive Services Task Force Recommendation Statement US Preventive Services
More informationHow Does Analysis of Competing Hypotheses (ACH) Improve Intelligence Analysis?
How Does Analysis of Competing Hypotheses (ACH) Improve Intelligence Analysis? Richards J. Heuer, Jr. Version 1.2, October 16, 2005 This document is from a collection of works by Richards J. Heuer, Jr.
More informationPerspectives on Large Simple Trials
Perspectives on Large Simple Trials Michael S Lauer, MD, FACC, FAHA Director, Division of Cardiovascular Sciences NHLBI/NIH May 8, 2012 Disclosures: None financial; my views only Three Questions Why trials?
More informationProstate Cancer Screening: Risks and Benefits across the Ages
Prostate Cancer Screening: Risks and Benefits across the Ages 7 th Annual Symposium on Men s Health Continuing Progress: New Gains, New Challenges June 10, 2009 Michael J. Barry, MD General Medicine Unit
More informationMisuse of Bisphosphonates. Dr Rukhsana Parvin Associate Professor Department of Medicine Enam Medical College & Hospital
Misuse of Bisphosphonates Dr Rukhsana Parvin Associate Professor Department of Medicine Enam Medical College & Hospital Introduction Bisphosphonates are chemically stable analogues of pyrophosphate compounds.
More information3 Phase III Clinical Trials
3 Phase III Clinical Trials Why are clinical trials needed? Examples that show anecdotal information may be misleading: Blood-letting High oxygen concentration for premature infants has harm Intermittent
More informationRisk Study. Section for Clinical Epidemiology and Biostatistics. Definition
Risk Study Section for Clinical Epidemiology and Biostatistics What is Risk? Definition The probability of some untoward event The likelihood that people who are exposed to certain factors (risk factors)
More informationReal World Evidence in the Treatment of Ovarian Cancer. Elizabeth Eisenhauer MD FRCPC Queen s University
Real World Evidence in the Treatment of Ovarian Cancer Elizabeth Eisenhauer MD FRCPC Queen s University Outline What is real world evidence (RWE) and how can it shape policy and practice? In ovarian cancer,
More informationClinical problems and choice of study designs
Evidence Based Dentistry Clinical problems and choice of study designs Asbjørn Jokstad University of Oslo, Norway Nov 21 2001 1 Manipulation with intervention Yes Experimental study No Non-experimental
More informationLecture 2. Key Concepts in Clinical Research
Lecture 2 Key Concepts in Clinical Research Outline Key Statistical Concepts Bias and Variability Type I Error and Power Confounding and Interaction Statistical Difference vs Clinical Difference One-sided
More informationCorporate Medical Policy
Corporate Medical Policy Saturation Biopsy for Diagnosis, Staging, and Management of Prostate File Name: Origination: Last CAP Review: Next CAP Review: Last Review: saturation_biopsy_for_diagnosis_ staging_and_management_of_prostate_cancer
More informationBrief interventions delivered in GP surgeries to improve quit rates
Brief interventions delivered in GP surgeries to improve quit rates Matrix Insight, in collaboration with Imperial College London, Kings College London and Bazian Ltd, were commissioned by Health England
More informationState of the art pharmacoepidemiological study designs for post-approval risk assessment
State of the art pharmacoepidemiological study designs for post-approval risk assessment Cardiac Safety Research Consortium Think Tank Round Table Meeting Thursday, March 6, 2014 Jennifer L. Lund, PhD
More informationWEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital
WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased
More informationHYPERTENSION IN THE ELDERLY A BALANCED APPROACH. Barry Goldlist October 31, 2014
HYPERTENSION IN THE ELDERLY A BALANCED APPROACH Barry Goldlist October 31, 2014 DISCLOSURE I have not accepted any money for myself from any pharmaceutical company in the 21 st century I have accepted
More informationSERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
More informationMusculoskeletal Annotated Bibliography
Musculoskeletal Annotated Bibliography Clinical Question: Is Kinesio taping effective in improving ROM and/or pain in the treatment of shoulder injuries? Thelen MD, Dauber JA, Stoneman PD. The clinical
More informationCHECK-LISTS AND Tools DR F. R E Z A E I DR E. G H A D E R I K U R D I S TA N U N I V E R S I T Y O F M E D I C A L S C I E N C E S
CHECK-LISTS AND Tools DR F. R E Z A E I DR E. G H A D E R I K U R D I S TA N U N I V E R S I T Y O F M E D I C A L S C I E N C E S What is critical appraisal? Critical appraisal is the assessment of evidence
More informationFixed Effect Combining
Meta-Analysis Workshop (part 2) Michael LaValley December 12 th 2014 Villanova University Fixed Effect Combining Each study i provides an effect size estimate d i of the population value For the inverse
More informationMeta-analysis of well-designed nonrandomized comparative studies of surgical procedures is as good as randomized controlled trials
Journal of Clinical Epidemiology 63 (2010) 238e245 SYSTEMATIC REVIEWS AND META ANALYSIS Meta-analysis of well-designed nonrandomized comparative studies of surgical procedures is as good as randomized
More informationCritical Appraisal Where Do I Start?
Critical Appraisal Where Do I Start? An Introduction to the New PHAC Toolkit Joanne Archer RN Btech MA CIC Education and Practice Coordinator, PICNet Why is Critical Appraisal of Studies Important? Decisions
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationexposure/intervention
Kathleen A. Kennedy, MD, MPH University of Texas Medical School at Houston Medical School Most clinical research evaluates an association between exposure/intervention outcome. 1 Does the investigator
More informationScreening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality
Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Sanoj Punnen, MD, MAS Assistant Professor of Urologic Oncology University of Miami, Miller School of Medicine and Sylvester
More informationEssential Skills for Evidence-based Practice Understanding and Using Systematic Reviews
J Nurs Sci Vol.28 No.4 Oct - Dec 2010 Essential Skills for Evidence-based Practice Understanding and Using Systematic Reviews Jeanne Grace Corresponding author: J Grace E-mail: Jeanne_Grace@urmc.rochester.edu
More informationWHAT IS EVIDENCE- BASED MEDICINE?
WHAT IS EVIDENCE- BASED MEDICINE? A Discussion of the Pros and Cons of the Trend Towards Statistical Evidence Guiding Medical Practice Dr Sandeep Gupta MBBS MA FRACGP FACNEM The term "Evidence-Based Medicine"
More informationRisk Benefit Assessment. Cristina E. Torres, Ph.D. UP-NIH Faculty and FERCAP Coordinator
Risk Benefit Assessment Cristina E. Torres, Ph.D. UP-NIH Faculty and FERCAP Coordinator Definition of Risk The term risk refers both to the probability of a harm resulting from an activity and to its magnitude.
More informationIs therapy a realistic option at the present time? Felipe Fregni LEASE DO NOT COPY. Spauding Neuromodulation Center Harvard Medical School
Is therapy a realistic option at the present time? Felipe Fregni Spauding Neuromodulation Center Harvard Medical School Arguments supporting therapeutic use of tdcs Questions to be answered: Is there a
More informationDr. Sonia Oveisi Assistant Professor of Qazvin University of Medical Science RESOURCES FOR EBM 6/2/2014 1
Dr. Sonia Oveisi Assistant Professor of Qazvin University of Medical Science RESOURCES FOR EBM 6/2/2014 1 Definitions of EBM EBM is the conscientious, explicit, and judicious use of current best evidence
More information